[{"address1": "126 East Lincoln Avenue", "city": "Rahway", "state": "NJ", "zip": "07065", "country": "United States", "phone": "908 740 4000", "website": "https://www.merck.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.", "fullTimeEmployees": 73000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert M. Davis J.D.", "age": 58, "title": "Chairman, President & CEO", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 4946636, "exercisedValue": 12137946, "unexercisedValue": 8920883}, {"maxAge": 1, "name": "Ms. Betty D. Larson", "age": 49, "title": "Executive VP & Chief Human Resources Officer", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 2294965, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard R. DeLuca Jr.", "age": 62, "title": "Executive VP & President of Merck Animal Health", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 2169938, "exercisedValue": 0, "unexercisedValue": 5823540}, {"maxAge": 1, "name": "Mr. Dalton E. Smart III", "age": 58, "title": "Senior VP of Finance, Principal Accounting Officer & Global Controller", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Peter  Dannenbaum", "title": "Vice President of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sanat  Chattopadhyay", "age": 65, "title": "Executive VP & President of Merck Manufacturing Division", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 2488990, "exercisedValue": 12488854, "unexercisedValue": 7539200}, {"maxAge": 1, "name": "Dr. Eric H. Rubin M.D.", "age": 66, "title": "Senior Vice President of Global Clinical Oncology & Early-stage Oncology", "yearBorn": 1959, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eliav  Barr M.D.", "age": 60, "title": "Chief Medical Officer & Head of Global Clinical Development of Merck Research Laboratories", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joerg  Koglin", "title": "Senior VP & Head of General Medicine - Global Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Katherine  Taylor", "title": "Senior Director and Head of Risk Evaluation & Adaptive Integrated Monitoring", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 5, "compensationRisk": 4, "shareHolderRightsRisk": 2, "overallRisk": 3, "governanceEpochDate": 1767225600, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://www.merck.com/investors/home.html", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 110.99, "open": 110.87, "dayLow": 110.22, "dayHigh": 112.4799, "regularMarketPreviousClose": 110.99, "regularMarketOpen": 110.87, "regularMarketDayLow": 110.22, "regularMarketDayHigh": 112.4799, "dividendRate": 3.4, "dividendYield": 3.08, "exDividendDate": 1765756800, "payoutRatio": 0.4286, "fiveYearAvgDividendYield": 3.05, "beta": 0.298, "trailingPE": 14.62037, "forwardPE": 14.824263, "volume": 9137817, "regularMarketVolume": 9137817, "averageVolume": 13487198, "averageVolume10days": 11639800, "averageDailyVolume10Day": 11639800, "bid": 0.0, "ask": 0.0, "bidSize": 600, "askSize": 300, "marketCap": 276080001024, "fiftyTwoWeekLow": 73.31, "fiftyTwoWeekHigh": 112.9, "allTimeHigh": 134.63, "allTimeLow": 0.265055, "priceToSalesTrailing12Months": 4.2979684, "fiftyDayAverage": 98.4204, "twoHundredDayAverage": 86.07485, "trailingAnnualDividendRate": 3.2, "trailingAnnualDividendYield": 0.028831428, "currency": "USD", "tradeable": false, "enterpriseValue": 297554935808, "profitMargins": 0.29632, "floatShares": 2478026480, "sharesOutstanding": 2482022536, "sharesShort": 37162304, "sharesShortPriorMonth": 27626151, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.015, "heldPercentInsiders": 0.00058, "heldPercentInstitutions": 0.801, "shortRatio": 2.34, "shortPercentOfFloat": 0.0167, "impliedSharesOutstanding": 2497783212, "bookValue": 20.845, "priceToBook": 5.3024707, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "earningsQuarterlyGrowth": 0.832, "netIncomeToCommon": 19033999360, "trailingEps": 7.56, "forwardEps": 7.45602, "lastSplitFactor": "1048:1000", "lastSplitDate": 1622678400, "enterpriseToRevenue": 4.632, "enterpriseToEbitda": 9.439, "52WeekChange": 0.09457314, "SandP52WeekChange": 0.19362879, "lastDividendValue": 0.85, "lastDividendDate": 1765756800, "quoteType": "EQUITY", "currentPrice": 110.53, "targetHighPrice": 135.0, "targetLowPrice": 83.0, "targetMeanPrice": 113.33333, "targetMedianPrice": 115.0, "recommendationMean": 1.89655, "recommendationKey": "buy", "numberOfAnalystOpinions": 27, "totalCash": 18214000640, "totalCashPerShare": 7.338, "ebitda": 31523000320, "totalDebt": 41373999104, "quickRatio": 1.09, "currentRatio": 1.661, "totalRevenue": 64234999808, "debtToEquity": 79.708, "revenuePerShare": 25.559, "returnOnAssets": 0.13755, "returnOnEquity": 0.39485002, "grossProfits": 50007998464, "freeCashflow": 14527875072, "operatingCashflow": 17064999936, "earningsGrowth": 0.87, "revenueGrowth": 0.037, "grossMargins": 0.77852, "ebitdaMargins": 0.49074, "operatingMargins": 0.40802, "financialCurrency": "USD", "symbol": "MRK", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Merck & Company, Inc.", "longName": "Merck & Co., Inc.", "averageAnalystRating": "1.9 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": -252322200000, "postMarketChangePercent": 0.08613009, "postMarketPrice": 110.6252, "postMarketChange": 0.095199585, "regularMarketChange": -0.459999, "regularMarketDayRange": "110.22 - 112.4799", "fullExchangeName": "NYSE", "averageDailyVolume3Month": 13487198, "fiftyTwoWeekLowChange": 37.22, "fiftyTwoWeekLowChangePercent": 0.50770706, "fiftyTwoWeekRange": "73.31 - 112.9", "fiftyTwoWeekHighChange": -2.3700027, "fiftyTwoWeekHighChangePercent": -0.020992052, "fiftyTwoWeekChangePercent": 9.457314, "dividendDate": 1767830400, "earningsTimestamp": 1770125400, "earningsTimestampStart": 1770125400, "earningsTimestampEnd": 1770125400, "earningsCallTimestampStart": 1770127200, "earningsCallTimestampEnd": 1770127200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 7.56, "epsForward": 7.45602, "epsCurrentYear": 8.96033, "priceEpsCurrentYear": 12.335483, "fiftyDayAverageChange": 12.109596, "fiftyDayAverageChangePercent": 0.12303949, "twoHundredDayAverageChange": 24.455147, "twoHundredDayAverageChangePercent": 0.2841149, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "corporateActions": [], "postMarketTime": 1768006694, "regularMarketTime": 1767992402, "exchange": "NYQ", "messageBoardId": "finmb_288502", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -0.414451, "regularMarketPrice": 110.53, "marketState": "CLOSED", "displayName": "Merck &", "trailingPegRatio": 1.1642, "__fetch_time": "2026-01-10"}]